Australia's most trusted
source of pharma news
Posted 20 May 2022 AM
Imugene has finally moved its novel cancer-killing virus therapy Vaxinia into clinical trials and has high hopes it can make MSD's PD-1 inhibitor Keytruda more effective in solid tumours.
The Sydney-based company acquired global exclusive license rights to the oncolytic virus technology developed by researchers at City of Hope, a world-renowned cancer research and treatment organisation in Los Angeles back in 2019.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.